Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
NCT01776684
·
clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
200
Enrollment
OTHER
Sponsor class
Conditions
EGFR Mutation Positive Non-small Cell Lung Cancer
Interventions
DRUG:
EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
Sponsor
Samsung Medical Center
Collaborators
[object Object]